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liver disease globally, with >240 million people infected and
>780 000 people dying because of complications of CHB, such
as liver cirrhosis and hepatocellular carcinoma (HCC) [1,2].
The prevalence and management of chronic hepatitis B virus
(HBV) infection differs among European countries. It is there-
fore an important public health problem in Europe, especially in
urban areas and countries with large immigrant populations
[3,4]. According to estimations of the WHO, there are
approximately 14 million people in Europe who are chronically
infected with HBV, resulting in approximately 36 000 related
deaths each year [5]. Furthermore, the epidemiology of HBV
infection differs substantially, with a low prevalence in north-
western Europe and an intermediate prevalence in eastern
Europe and some parts of southern Europe [6]. This coincides
with similar differences in budget constraints that probably
affect HBV diagnostics and treatment reimbursements.
CHB treatment is aimed at suppressing viral replication by
the use of interferon or nucleotide/nucleoside analogues (NAs).
As the latter are used for long durations, ﬁrst-generation
agents, such as lamivudine and adefovir, are compromised by
the emergence of resistance [7]. The European Association for
the Study of the Liver Clinical Practice Guidelines recommend
entecavir or tenofovir as the antiviral of choice for the ﬁrst-line
treatment of CHB [8]. Baseline and on-treatment analyses,
including HBV DNA quantiﬁcation, ultrasound, biochemistry,
and invasive or non-invasive tests estimating liver ﬁbrosis, are
required for optimal management. However, the availability and
reimbursement of both diagnostics and drugs may also vary
over Europe, inﬂuencing the management of CHB [9–11].
There have been few studies in this ﬁeld [12,13]. Therefore,
we aimed to determine the differences in facilities and the
clinical practice of physicians involved in the management of
chronic HBV infection in Europe.Materials and methodsA comprehensive survey was sent to 23 members of the
ESCMID Study Group for Viral Hepatitis with renowned
expertise in the ﬁeld of viral hepatitis diagnosis and manage-
ment in their countries. The survey inquired about (a) the
prevalence of hepatitis B surface antigen (HBsAg), (b) the
availability and reimbursement of diagnostics (HBV DNA and
transient elastography) and anti-HBV drugs (pegylated inter-
feron-α, lamivudine, entecavir, and tenofovir disoproxilClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infectfumarate), (c) clinical practice in both the management of
chronic HBV infection and antiviral prophylaxis in immuno-
suppressed patients, and ﬁnally (d) the duration of treatment in
both HBeAg-positive and HBeAg-negative patients.
The study period was June 2013 to June 2014, with updated
ﬁnal corrections in April 2015.
The facilities of each country were evaluated with respect to
their income category (low, lower middle, upper middle and
high income) according to the World Bank stratiﬁcation cor-
responding to gross national income per capita in 2013 [14].
World Bank data were used because they provide a standard-
ized categorization for countries.
Restriction was deﬁned as the unavailability of a diagnostic or
drug or it not being covered by the reimbursement policy of
the given country.
The surveys were sent from the experts as a Word ﬁle, and
were transported into SPSS Version 17 (SPSS, Chicago, IL,
USA). Descriptive statistics and frequencies were analysed.
Description was qualitative and grouped according to the
availability of facilities in each country, and the World Bank
categorization was added.ResultsSixteen of 23 expert physicians responded (69%) by ﬁlling in the
questionnaire: three from Italy, two each from France and
Turkey, and one each from Albania, Hungary, Iran, The
Netherlands, Portugal, Romania, Serbia, Spain, and the UK. All
experts were able to answer all questions. The countries
included in the study were categorized according to the the
World Bank Income Grouping as follows: upper middle in-
come—Albania, Hungary, Iran, Romania, and Serbia; and high
income—France, Italy, The Netherlands, Portugal, Spain,
Turkey, and the UK.
Prevalence and diagnostics
A summary of the results is given in Table 1. The HBsAg
prevalence is low (<1%) in France, Hungary, Italy, The
Netherlands, Portugal, Spain, and the UK, intermediate (1–5%)
in Turkey, Romania, and Serbia, and high (>5%) in Albania and
Iran. HBV DNA testing is commonly available and reimbursed
in France, Hungary, Italy, The Netherlands, Portugal, Spain,
Turkey, and the UK; it is available but reimbursed with some
restrictions (baseline, at 6 months after therapy initiation and
annually afterwards, or two or three times in a year, etc.) in
Hungary, Iran, Romania, and Serbia. In Albania, only one uni-
versity hospital and several private laboratories offer this
facility.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1027–1032
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Clinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anA summary of the availability and reimbursement status of
HBV diagnostics and drugs is given in Table 2. Liver stiffness
measurement (Fibroscan) is available and reimbursed in France,
Hungary, Italy, Portugal, Serbia, and Spain; it is available but not
reimbursed in Iran, The Netherlands, Turkey, and the UK. This
test is reimbursed and available in only one hospital in Albania. It
is used for every patient at baseline and at follow-up in France,
Hungary, Italy, Portugal, The Netherlands, and Spain, whereas it
is used in some cases in Iran, Romania, Serbia, Turkey, the UK,
and Romania, where ﬁbrosis measurements are based on
composite biochemical indexes (FibroMax and FibroTest).
Treatment
Pegylated interferon-α is freely available for HBV patients in
France, Hungary, Italy, The Netherlands, Portugal, Spain, and
the UK, whereas there are some restrictions (measurement of
alanine transaminase (ALT) and/or HBV DNA level; results of
liver biopsy or Fibrotest) in Albania, Iran, Romania, Serbia, and
Turkey. In Romania, it is recommended primarily for young
patients with moderate ALT and HBV DNA values, and is
recommended optimally after HBV genotyping.
As regards oral HBV therapy, lamivudine is available and
reimbursed for HBV in Albania, France, Hungary, Iran, Italy, The
Netherlands, Portugal, Spain, Turkey, and the UK. It is available
and reimbursed with some restrictions (ALT and/or HBV DNA
level; degree of liver ﬁbrosis) on initiation in Romania and Serbia.
Tenofovir is available and reimbursed for HBV in France,
Hungary, Iran, Italy, The Netherlands, Portugal, Spain, Turkey,
and the UK. It is available and reimbursed with some restrictions
(ALT and/or HBV DNA level; biopsy ﬁndings) in Albania and
Serbia. In Romania, tenofovir was approved for treatment and
therefore placed on the list of reimbursed drugs at the end of
2014, so it is now one of the ﬁrst-choice drugs for treatment
initiation. Entecavir is available and reimbursed for HBV in
France, Hungary, Italy, The Netherlands, Portugal, Spain, Turkey,
and the UK. It is available and reimbursed with some restrictions
(ALT and/or HBV DNA level; biopsy ﬁndings) in Romania. It is
neither available nor reimbursed in Albania, Iran, and Serbia.
As regards HBV prophylaxis (i.e. for those given immuno-
suppressive drugs), all antivirals are freely reimbursed in France,
Hungary, Italy, The Netherlands, Portugal, Spain, Turkey, and the
UK. Lamivudine and tenofovir are reimbursed in Albania. In Iran
and Serbia, lamivudine is reimbursed, and tenofovir and entecavir
are reimbursed if the HBV DNA level is higher than a certain
value. Entecavir and tenofovir are reimbursed in Romania,
including for patients who are hepatitis B core antibody-positive
and hepatitis B surface antibody (anti-HBs)-negative.
Among lamivudine users, in the case of a suboptimal
response (i.e. detectable HBV DNA after 6 months of lam-
ivudine therapy), switching to tenofovir is reimbursed ind Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1027–1032
TABLE 2. Availability and reimbursement status of hepatitis B virus (HBV) diagnostics and drugs
HBV diagnostics HBV drugs
HBV prophylaxis WB country groupCountry HBV DNA Liver stiffness measurement IFN LAM TDF ETV
Albania A-Ra A-R A-Ra A-R A-Ra NA-NR LAM, TDF UMI
Romania A-Ra A-R A-Ra A-Ra A-R A-Ra TDF, ETV UMI
Serbia A-Ra A-R A-Ra A-Ra A-Ra NA-NR LAM, TDFa, ETVa UMI
Hungary A-Ra A-R A-R A-R A-R A-R LAM, TDF, ETV UMI
Iran A-Ra NR A-Ra A-R A-R NA-NR LAM, TDFa, ETVa UMI
Turkey A-R NR A-Ra A-R A-R A-R LAM, TDF, ETV UMI
France A-R A-R A-R A-R A-R A-R LAM, TDF, ETV HI
Italy A-R A-R A-R A-R A-R A-R LAM, TDF, ETV HI
The Netherlands A-R NR A-R A-R A-R A-R LAM, TDF, ETV HI
Portugal A-R A-R A-R A-R A-R A-R LAM, TDF, ETV HI
Spain A-R A-R A-R A-R A-R A-R LAM, TDF, ETV HI
UK A-R NR A-R A-R A-R A-R LAM, TDF, ETV HI
A-R, available and reimbursed; ETV, entecavir; HI, high-income country; IFN, interferon; LAM, lamivudine; NA-NR, not available and not reimbursed; NR, not reimbursed; TDF,
tenofovir; UMI, upper-middle-income country; WB, World Bank.
aWith some restrictions.
1030 Clinical Microbiology and Infection, Volume 21 Number 11, November 2015 CMIAlbania, France, Iran, and Turkey, and switching to tenofovir or
the addition of adefovir is reimbursed in Romania.
As regards duration of treatment in HBeAg-positive patients,
reimbursement is arranged as long as HBeAg remains positive,
and for 12 months after anti-HBe seroconversion in Albania,
Hungary, The Netherlands, Turkey, and the UK. It is reim-
bursed as long as HBeAg remains positive, and also, according
to the physician’s decision, after anti-HBs seroconversion (for
an indeﬁnite duration) in France, Iran, Italy, Portugal, and Spain.
In Serbia, it is reimbursed for as long as the physician decides to
continue it, and the length of treatment is left to be determined
by the physician according to biochemical and virological re-
sponses, in both HBeAg-positive and HBeAg-negative patients.
In Romania, it is reimbursed according to the biochemical and
virological responses, as evaluated every 6 months up to 5
years, in both HBeAg-positive and HBeAg-negative patients
until anti-HBs seroconversion and 6 months afterwards.
Treatment of HBeAg-negative patients continues as long as
HBsAg is positive in France (one expert), Turkey, and the UK,
whereas it is given until anti-HBs seroconversion in Albania,
France (one expert), and Italy (two experts). If there is a
decrease of <2 log10 in HBV DNA after 6 months of therapy,
lamivudine is stopped in Romania. It is given as long as HBsAg is
positive, and also, according to the physician’s decision, after
HBsAg loss or anti-HBs seroconversion (for an indeﬁnite
duration) in Hungary, Italy (one expert), The Netherlands,
Portugal, Serbia, and Spain. It is reimbursed for a ﬁxed duration
independently of HBsAg seroconversion in Iran.DiscussionApproximately 25% of patients with CHB are at risk of devel-
oping cirrhosis, decompensation, liver failure or HCC during
their lifetimes [15]. In some Asian countries, HCC is one of theClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology and Infecttop three causes of death in males, largely because of HBV
infection [16]. In most European countries, immigrants are
responsible for a substantial proportion of chronic HBV pa-
tients [9,17,18].
Vaccination of infants is very effective in preventing HBV
infection, and universal programmes have resulted in a dramatic
decrease in the prevalence of HBV in young children. However,
the serious complications of HBV infection appear later in life,
usually after the ﬁfth decade [19]. However, there is still a large
residual pool of chronically infected patients [20]. Treatment of
patients with chronic HBV infection is a means of reducing the
morbidity associated with the disease, and also contributes to
the decrease in transmission [21]. However, the diagnosis and
management of HBV infection are costly, and are not
completely covered by reimbursement policies in some Euro-
pean countries.
Our study is the ﬁrst to clearly and comprehensively show
that there are no signiﬁcant restrictions on diagnostics and drug
availability in several upper-middle-income and high-income
countries, including France, Hungary, The Netherlands, the
UK, Spain, Portugal, and Italy, which already have a low prev-
alence of HBV. On the other hand, some upper-middle-income
countries with moderate to high prevalence rates, such as
Albania and Iran, have restrictions on diagnostics and/or man-
agement. Romania has very recently made important steps by
approving the reimbursement of all drugs and relaxing the
initiation and treatment duration criteria.
The economic aspect of HBV management is a key factor.
The economic development status appears to be a factor
determining the availability and reimbursement of HBV di-
agnostics and drugs. This study conﬁrms that HBV preva-
lence rates are higher in upper-middle-income countries
(except Hungary) than in high-income countries. The coun-
tries with higher prevalence rates need higher budgets for
effective management of the disease, but are currentlyious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21, 1027–1032
CMI Ozaras et al. Availability of resources for HBV in Europe 1031lacking such funds. This makes the ﬁght against HBV more
complicated.
A sensitive PCR assay is needed for the diagnosis of HBV
infection, and also for on-treatment monitoring of treatment
response [8]— for patients treated with NAs, HBV DNA levels
should be checked at the third month, in order to determine
virological response, and then every 3–6 months. This is
especially important when a drug with a low genetic barrier to
resistance, such as lamivudine, is used. In Albania, Iran, and
Serbia, there are barriers to the prescription of tenofovir and/
or entecavir. However, these countries do not have unre-
stricted use of HBV DNA measurement. For example, in
Romania, HBV DNA measurement is available and free at
baseline and at follow-up every 6 months after treatment
initiation. This is important, because long-term lamivudine use
is limited by the emergence of resistance. Switching to tenofovir
is recommended in cases of lamivudine resistance [8,22]. In
addition, in lamivudine-experienced patients, entecavir treat-
ment results in high rates of virological resistance, of approxi-
mately 50% at 5 years, which is not an issue in those patients
without lamivudine resistance mutations [23,24]. Tenofovir is
reimbursed in France, Iran, Turkey, Romania and Albania when
lamivudine fails, and switching to entecavir is reimbursed in
Romania only if no resistance to this agent is demonstrated. A
recent study from Romania reported a 15.6% entecavir resis-
tance rate among lamivudine-resistant patients in a median
follow-up of 96 weeks [25].
A ﬁnite duration of treatment and the absence of resistance
are the main advantages of interferon-α therapy, although its
use is limited by a moderate antiviral effect and poor tolerability
[8]. A pretreatment low viral load, high ALT levels and high
liver biopsy inﬂammation scores in HBeAg-positive patients are
predictors of anti-HBe seroconversion [8]. It is reimbursed,
with some restrictions, in Albania, Iran, The Netherlands,
Romania, Turkey, and the UK.
Hepatitis B reactivation is a potentially serious complication
of cancer chemotherapy or immunosuppressive drugs, and may
occur during or after therapy [26]. In our study group, lam-
ivudine is reimbursed, and tenofovir and entecavir are reim-
bursed if the HBV DNA level is higher than a certain value, in
Iran and Serbia. This is not in line with the recent American
Association for the Study of the Liver and European Association
for the Study of the Liver Guidelines, which recommend pre-
emptive NA use for HBsAg-positive candidates for chemo-
therapy and immunosuppressive therapy (regardless of HBV
DNA levels) and for 12 months after cessation of therapy
[8,27]. Prophylactic lamivudine has been shown to reduce the
risk of HBV reactivation and the associated morbidity and
mortality in immunocompromised patients. However, it is
recommended that patients with high HBV DNA levels and/orClinical Microbiology and Infection © 2015 European Society of Clinical Microbiology anthose receiving lengthy and repeated cycles of immunosup-
pression should be given potent drugs with a high barrier to
resistance, i.e. entecavir or tenofovir [8]. Therefore, revision of
reimbursement policies for these patients should receive high
priority, as the number of patients receiving these immuno-
suppresive drugs is growing.
The optimal duration of HBV treatment is not well estab-
lished, and the ideal endpoint, HBsAg loss, is infrequently
achievable with the currently available anti-HBV agents. How-
ever, the induction of a sustained virological and biochemical
response after discontinuation of therapy in HBeAg-negative
patients and durable anti-HBe seroconversion, in addition to
these virological and biochemical outcomes, in HBeAg-positive
patients are accepted as satisfactory endpoints [8]. It must be
noted that, in Serbia, HBV therapy is allowed to be given ac-
cording to the physician’s choice, independently of anti-HBe
seroconversion, in HBeAg-positive patients. It is allowed to
be given for a ﬁxed duration independently of HBsAg loss in
Iran.
The prevalence of chronic HBV infection is much higher in
southern and eastern European than in western European
countries. Despite the availability of European guidelines, the
policies for diagnostics and management of chronic HBV
infection vary signiﬁcantly among European countries. The main
discrepancy is that countries with higher prevalence rates have
limited access to optimal facilities.Transparency declarationJoop E. Arends is involved in advisory boards with MSD, Gilead,
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